Clerk of the House of Representatives
Legislative Resource Center
135 Cannon Building
Washington, DC 20515
http://lobbyingdisclosure.house.gov 		Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510
http://www.senate.gov/lobby
LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Organization/Lobbying Firm Self Employed Individual
Carol G Holladay & Associates

2. Address

Address1
507 Independence Ave SE
 Address2
​Apt, suite, floor, etc.
City
Washington
 State
DC
 Zip Code
20003
 Country
USA

3. Principal place of business (if different than line 2)

City
​Washington
 State
​DC
 Zip Code
​20003
 Country
​USA
4a. Contact Name b. Telephone Number c. E-mail
​Ms.
​Carol Graves Holladay
​2026697039
​carol@carolgholladayassociates.com
5. Senate ID#
​401106369-24
7. Client Name Self Check if client is a state or local government or instrumentality
​Southeast Georgia Hospital System
6. House ID#
​454410002
TYPE OF REPORT 8. Year
​2026
 Q1 (1/1 - 3/31) Q2 (4/1 - 6/30) Q3 (7/1 - 9/30) Q4 (10/1 - 12/31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report Termination Date
​
11. No Lobbying Issue Activity
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13
12. Lobbying 13. Organizations
INCOME relating to lobbying activities for this reporting period was: EXPENSE relating to lobbying activities for this reporting period were:
Less than $5,000
Less than $5,000
$5,000 or more $
​24,000.00
$5,000 or more $
​
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options.
Method A. Reporting amounts using LDA definitions only

Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Signature
Digitally Signed By: Carol G Holladay
 Date
7/20/2026 3:59:46 PM

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

FY2027 Appropriations, ACA Subsidy Sunset, Funding for HHS/NIH, Medicare & Medicaid, Reductions of personnel at HHS, Research Funding, PACT Act with VA - funding for community care - reimbursements from VA
Tracking and outreach to delegation:
S.3345 - PBM Price Transparency and Accountabity Act
HR 5256 - 340B Access Act
HR 6240 Rural Hospital Closure Relief Act - Tracking Grid by state to compare what programs are activated


Tracking OMB Order on political appointees reviewing discretionary grant applications.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA)

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Carol
Holladay
Ms
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

Tracking -a federal district court vacated a Health Resources and Services Administration (HRSA) policy restricting 340B disproportionate share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act.
share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act.

Tracking Bills - S. 3206 Transgender Health Care Access Act, S. 2709 and HR 5081 Telehealth Modernization Act, HR 6468 Rural Residency Placement & Development Act of 2025 - the area is challenged with med students match with this region which challenges the ability to recruit new health care professionals to remain in the area. HR5821 - Rural Hospital Fairness Act, S891 - Bipartisan Health Act, S526 PBM Transparency Act - provides for full transparency in drug pricing to ensure any savings go back to patients - the Federal Trade Commission will complete a 6(b) study examining the effects of consolidation on pricing in the PBM industry, as well as other potentially abusive behavior by PBMs. The bill instructs the FTC to provide policy recommendations to Congress to improve competition and protect consumers. The hospital supports any mechanism for drug price transparency for patients. S527 - Prescription Pricing for People Act of 2025 - A study by FTC to study role of intermediaries (PBMs) in pharm. supply chain and provide recommendations for improvement of costs to patients. S927 Protecing Pharmacies in Medicaid Act - PBMs charge Medicaid more than they pay pharmacies for a particular drug, increases corporate profits while driving up costs for Medicaid. PBMs use of spread pricing has also been linked to the increasing failure rate for independent pharmacies, which provide a critical source of health care and community for rural communities. HR267 Health Care Transparency Act - statutory authority for requirements for hospitals and health insurance plans to disclose certain information about the costs for items and services. We need to ensure requirements are within appropriate information to be disclosed - challenged with varied reimbursement rates. HR 2214 - DRUG Act. The bill is impacting prescription drug costs, access, and manufacturing practices. These include the Inflation Reduction Act's provisions for Medicare Part D, amendments to the Federal Sentencing Guidelines, and potential changes related to PBMs and direct-to-consumer advertising. Supporting best and most affordable care for patients.


Tracking House Bills on price transaparency, drug controls, community care
H.R. 9393 - Lower Costs, More Transparency Act of 2026 (Guthrie, Pallone): Codifies existing price transparency rules for hospitals and health plans American Hospital Association.
H.R. 9390 - Prices on the Wall Act of 2026 (Miller-Meeks): Requires hospitals to post service pricing physically on their walls American Hospital Association.
H.R. 9397 - Premium Transparency Act (Pfluger, Moran): Mandates insurers to disclose how much of premiums go toward healthcare costs subscriber.politicopro.com.
H.R. 9396 - Prior Authorization Accountability Act (Goldman-TX): Improves transparency and consistency in prior authorization for Medicare Advantage plans American Hospital Association.
H.R. 5243 - Medicare Advantage Data Transparency Amendment: Increases data transparency for supplemental benefits under Medicare Advantage House Committee on Energy and Commerce.
H.R. 9395 - Transparency in Medicare Advantage Steering Act (Ocasio-Cortez): Enhances oversight and transparency in Medicare Advantage steering House Committee on Energy and Commerce.
Access to Care & Community Health
H.R. 8201 - Expanding Community Access to Health Services Act (Lee-NV): Requires community health centers to provide behavioral health and substance use disorder services, with related funding AACOM.
H.R. 9389 - Nutrition Education and Chronic Disease Prevention in Community Health Centers Act of 2026 (Harshbarger): Expands nutrition education and chronic disease prevention services at Federally Qualified Health Centers AACOM.
H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 (Kelly, DelBene): Reduces variation in prior authorization methods for Medicare Advantage plans American Hospital Association.
Illicit Drug Control
H.R. 1266 - Combatting Illicit Xylazine Act (Panetta, Pfluger): Places xylazine on the controlled substances list subscriber.politicopro.com.
H.R. 7970 - STOP Nitazenes Act (Latta): Places nitazenes on the controlled substances list subscriber.politicopro.com.
H.R. 2004 - Tylers Law (Lieu, Latta): Expands naloxone access and overdose prevention measures House Committee on Energy and Commerce.
H.R. 1561 - ALERT Communities Act (Crockett, Gooden): Supports community-based overdose prevention and response House Committee on Energy and Commerce.
H.R. 7994 - HERO Act (Ruiz): Enhances harm reduction and overdose prevention services House Committee on Energy and Commerce.
H.R. 5880 - Fight Illicit Pill Presses Act (Hageman, Stansbury) & H.R. 8005 - Stop Pills That Kill Act (Evans): Target illicit drug manufacturing and distribution House Committee on Energy and Commerce.
H.R. 7184 - PRESS Act (McDowell): Addresses illicit drug production and distribution




17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA)

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Carol
Holladay
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

Address
​
City
​
State
​
Zip Code
​
Country
​

21. Client new principal place of business (if different than line 20)

City
​
State
​
Zip Code
​
Country
​

22. New General description of client’s business or activities

​

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

First Name
Last Name
Suffix
First Name
Last Name
Suffix
1
​
​
​
3
​
​
​
2
​
​
​
4
​
​
​

ISSUE UPDATE

24. General lobbying issue that no longer pertains

​
​
​
​
​
​
​
​
​

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

Name Address Principal Place of Business
(city and state or country)
Street Address
City State/Province Zip Country
City
State Country

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

1 2 3

FOREIGN ENTITIES

27. Add the following foreign entities:

Name Address Principal place of business
(city and state or country) 		Amount of contribution for lobbying activities Ownership percentage in client
Street Address
City State/Province Country
City
State Country
%

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

1 3 5
2 4 6

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?

Lobbyist Name Description of Offense(s)